Medifast (NYSE:MED) Director Buys $342,069.42 in Stock

Medifast Inc (NYSE:MED) Director Parsa Kiai purchased 29,337 shares of Medifast stock in a transaction that occurred on Wednesday, August 19th. The stock was purchased at an average price of $11.66 per share, with a total value of $342,069.42. Following the completion of the purchase, the director directly owned 619,331 shares in the company, valued at $7,221,399.46. This trade represents a 4.97% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Parsa Kiai also recently made the following trade(s):

• On Thursday, August 20th, Parsa Kiai acquired 43,150 shares of Medifast stock. The stock was purchased at an average cost of $11.60 per share, for a total transaction of $500,540.00.

Medifast Trading Up 2.2%

MED stock traded up $0.25 during trading hours on Friday, hitting $11.87. 54,923 shares of the stock were exchanged, compared to its average volume of 231,125. Medifast Inc has a 12 month low of $9.22 and a 12 month high of $14.67. The firm has a market capitalization of $132.71 million, a P/E ratio of -5.09 and a beta of 0.65. The company has a 50-day simple moving average of $10.92 and a two-hundred day simple moving average of $11.06.

Medifast (NYSE:MED) last announced its earnings results on Monday, August 3rd. The specialty retailer reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.37. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.69%. The company had revenue of $76.38 million during the quarter, compared to analysts’ expectations of $72.70 million. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. On average, equities research analysts predict that Medifast Inc will post -1 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on MED. Zacks Research lowered shares of Medifast from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. Weiss Ratings upgraded shares of Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research report on Monday. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $12.00.

Institutional Trading of Medifast

Institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets lifted its holdings in shares of Medifast by 103.1% in the third quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after acquiring an additional 1,187 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Medifast during the 3rd quarter valued at approximately $37,000. Intesa Sanpaolo Wealth Management acquired a new position in Medifast during the 4th quarter worth approximately $47,000. State of Wyoming acquired a new position in Medifast during the 4th quarter worth approximately $59,000. Finally, Ancora Advisors LLC acquired a new position in Medifast during the 2nd quarter worth approximately $75,000. 95.51% of the stock is currently owned by institutional investors.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.